dc.contributor.author | Spain, L | |
dc.contributor.author | Larkin, J | |
dc.date.accessioned | 2017-04-10T16:08:30Z | |
dc.date.issued | 2016-06-01 | |
dc.identifier.citation | Immunotherapy, 2016, 8 (6), pp. 677 - 679 | |
dc.identifier.issn | 1750-743X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/574 | |
dc.identifier.eissn | 1750-7448 | |
dc.identifier.doi | 10.2217/imt.16.6 | |
dc.format | Print | |
dc.format.extent | 677 - 679 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FUTURE MEDICINE LTD | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Melanoma | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Treatment Outcome | |
dc.subject | Immunotherapy | |
dc.subject | Survival Analysis | |
dc.subject | Clinical Trials as Topic | |
dc.subject | CTLA-4 Antigen | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Programmed Cell Death 1 Receptor | |
dc.subject | Drug-Related Side Effects and Adverse Reactions | |
dc.subject | Ipilimumab | |
dc.subject | B7-H1 Antigen | |
dc.subject | Nivolumab | |
dc.title | Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.2217/imt.16.6 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2016-06 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Immunotherapy | |
pubs.issue | 6 | |
pubs.notes | 12 months | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 8 | |
pubs.embargo.terms | 12 months | |
icr.researchteam | Melanoma and Kidney Cancer | |
dc.contributor.icrauthor | Spain, Lavinia | |